Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pd-1 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05284539
What this trial is testing

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 760
Testing effectiveness (Phase 2)Study completedNCT03321630
What this trial is testing

A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies

Who this might be right for
GastroEsophageal CancerGastric Cancer
NYU Langone Health 24
Testing effectiveness (Phase 2)Study completedNCT05162352
What this trial is testing

Donafenib Plus Sintilimab for Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University 30
Testing effectiveness (Phase 2)UnknownNCT05509478
What this trial is testing

Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma

Who this might be right for
Biliary Tract Cancer
The First Hospital of Jilin University 46
Testing effectiveness (Phase 2)UnknownNCT05721651
What this trial is testing

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Who this might be right for
Gastric Cancer
Wu Jun 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05400070
What this trial is testing

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Who this might be right for
SintilimabLung CancerAnlotinib+1 more
Tang-Du Hospital 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06620822
What this trial is testing

Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 296
Testing effectiveness (Phase 2)UnknownNCT03939962
What this trial is testing

Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma

Who this might be right for
Gastric Cancer
Henan Cancer Hospital 60
Not applicableUnknownNCT05288569
What this trial is testing

IrAE Prediction of Anti-PD-1/L1 in Lung Cancer

Who this might be right for
Immune Checkpoint InhibitorsLung Cancer
Peking Union Medical College Hospital 120
Testing effectiveness (Phase 2)UnknownNCT05659186
What this trial is testing

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Who this might be right for
Thyroid Cancer
West China Hospital 20
Not applicableUnknownNCT04984096
What this trial is testing

Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer

Who this might be right for
Esophageal Cancer
Shanghai Chest Hospital 50
Testing effectiveness (Phase 2)Study completedNCT04181788
What this trial is testing

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Who this might be right for
Advanced MalignanciesNon-small-cell Lung Cancer
Pfizer 155
Testing effectiveness (Phase 2)Looking for participantsNCT07233252
What this trial is testing

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Who this might be right for
Renal Pelvic CarcinomaTislelizumabPD-1 Inhibitor+2 more
Tianjin Medical University Second Hospital 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06999252
What this trial is testing

Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients

Who this might be right for
Colon Cancer
Fudan University 20
Not applicableUnknownNCT06031636
What this trial is testing

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

Who this might be right for
Malignant Pleural Mesothelioma, Advanced
Tianjin Medical University Second Hospital 15
Testing effectiveness (Phase 2)Looking for participantsNCT06391190
What this trial is testing

Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer

Who this might be right for
Locally Advanced Cervical CarcinomaConcurrent ChemoradiotherapyImmunotherapy
RenJi Hospital 20
Testing effectiveness (Phase 2)UnknownNCT06487715
What this trial is testing

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Who this might be right for
Gastric Cancer Peritoneal Metastases
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 42
Large-scale testing (Phase 3)UnknownNCT04557020
What this trial is testing

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Who this might be right for
Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital 200
Testing effectiveness (Phase 2)Study completedNCT03322540
What this trial is testing

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Who this might be right for
Lung Cancer
Incyte Corporation 154
Not applicableUnknownNCT04771715
What this trial is testing

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Who this might be right for
Advanced Colorectal Carcinoma
Peking Union Medical College Hospital 100
Next Page